Transfusion reactions after transfusion of platelets stored in PAS-B, PAS-C, or plasma: a nationwide comparison

Transfusion

Volumn 58, Issue 4, 2018, Pages 1021-1027

  van Hout, Fabienne M A ^a,b   van der Meer, Pieter F ^a   Wiersum Osselton, Johanna C ^c   Middelburg, Rutger A ^a,b   Schipperus, Martin R ^c,d   van der Bom, Johanna G ^a,b   Kerkhoffs, Jean Louis ^a,d  

^a SANQUIN RESEARCH   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Dutch National Hemovigilance and Biovigilance Office   (Netherlands)

^d HAGA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ADDITIVE; PRESERVATION SOLUTION;

ALLERGIC REACTION; ARTICLE; BLOOD SAFETY; BLOOD TRANSFUSION REACTION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEBRILE NONHEMOLYTIC TRANSFUSION REACTION; HUMAN; NETHERLANDS; OBSERVATIONAL STUDY; PLASMA; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; TRANSFUSION RELATED ACUTE LUNG INJURY; BLOOD BUFFY COAT; BLOOD STORAGE; CLINICAL TRIAL; CYTOLOGY; DRUG EFFECT; HYPERSENSITIVITY; MULTICENTER STUDY; ODDS RATIO; PROCEDURES; RETROSPECTIVE STUDY; THROMBOCYTE;

BLOOD BUFFY COAT; BLOOD PLATELETS; BLOOD PRESERVATION; BLOOD SAFETY; HUMANS; HYPERSENSITIVITY; NETHERLANDS; ODDS RATIO; ORGAN PRESERVATION SOLUTIONS; PLASMA; PLATELET TRANSFUSION; RETROSPECTIVE STUDIES; TRANSFUSION REACTION;

EID: 85045106312     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14509     Document Type: Article

References (32)

1. Estcourt LJ. Why has demand for platelet components increased? A review. Transfus Med 2014;24:260-8.
2. Kreuger AL, Caram-Deelder C, Jacobse J, et al. Effect of storage time of platelet products on clinical outcomes after transfusion: a systematic review and meta-analyses. Vox Sang 2017; 112:291-300.
3. Goodnough LT, Riddell J 4th, Lazarus H, et al. Prevalence of platelet transfusion reactions before and after implementation of leukocyte-depleted platelet concentrates by filtration. Vox Sang 1993;65:103-7.
4. Heddle NM, Klama L, Singer J, et al. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994;331:625-8.
5. Tobian AA, Savage WJ, Tisch DJ, et al. Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction. Transfusion 2011;51:1676-83.
6. Karafin M, Fuller AK, Savage WJ, et al. The impact of apheresis platelet manipulation on corrected count increment. Transfusion 2012;52:1221-7.
7. Honohan A, Tomson B, van der Bom J, et al. A comparison of volume-reduced versus standard HLA/HPA-matched apheresis platelets in alloimmunized adult patients. Transfusion 2012;52:742-51.
8. Azuma H, Hirayama J, Akino M, et al. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol). Transfusion 2009;49:214-8.
9. Yanagisawa R, Shimodaira S, Kojima S, et al. Replaced platelet concentrates containing a new additive solution, M-sol: safety and efficacy for pediatric patients. Transfusion 2013;53:2053-60.
10. Cohn CS, Stubbs J, Schwartz J, et al. A comparison of adverse reaction rates for PAS C versus plasma platelet units. Transfusion 2014;54:1927-34.
11. Tobian AA, Fuller AK, Uglik K, et al. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME). Transfusion 2014;54:1523-9; quiz 1522.
12. Kerkhoffs JL, Eikenboom JC, Schipperus MS, et al. A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood 2006;108:3210-5.
13. de Wildt-Eggen J, Nauta S, Schrijver JG, et al. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion 2000;40:398-403.
14. Blood Transfusion Guideline [Internet]. Amsterdam: Sanquin; 2011 [cited 2017 Mar 20]. Available from: http://www.isbtweb.org/fileadmin/user_upload/blood-transfusion-guideline.pdf.
15. Wiersum-Osselton JC, van Tilborgh-de Jong AJ, Zijlker-Jansen PY, et al. Variation between hospitals in rates of reported transfusion reactions: is a high reporting rate an indicator of safer transfusion? Vox Sang 2013;104:127-34.
16. Transfusion reactions and incidents annual report 2014. Hemovigilance. Extended version [Internet]. Leiden: TRIP Hemovigilance and Biovigilance Office; 2015 [cited 2017 Mar 20]. Available from: https://www.tripnet.nl/en/hemovigilance/definitions/
17. Working party on haemovigilance [Internet]. Amsterdam: International Society of Blood Transfusion; 2011 [cited 2017 Mar 20]. Available from: http://www.ihn-org.com/wp-content/uploads/2011/06/ISBT_definitions_final_2011_TRALIcorrection2013.pdf.
18. Kreuger AL, Middelburg RA, Kerkhoffs JH, et al. Storage medium of platelet transfusions and the risk of transfusion-transmitted bacterial infections. Transfusion 2017;57:657-60.
19. Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol 1976;103:226-35.
20. Andreu G, Vasse J, Herve F, et al. [Introduction of platelet additive solutions in transfusion practice. Advantages, disadvantages and benefit for patients]. Transfus Clin Biol 2007;14:100-6. French.
21. Savage WJ, Tobian AA, Savage JH, et al. Scratching the surface of allergic transfusion reactions. Transfusion 2013;53:1361-71.
22. van der Meer PF. PAS or plasma for storage of platelets? A concise review. Transfus Med 2016;26:339-42.
23. Klinger MH, Josch M, Klüter H. Platelets stored in a glucose-free additive solution or in autologous plasma—an ultrastructural and morphometric evaluation. Vox Sang 1996;71:13-20.
24. Johnson L, Schubert P, Tan S, et al. Extended storage and glucose exhaustion are associated with apoptotic changes in platelets stored in additive solution. Transfusion 2016;56:360-8.
25. Gyongyossy-Issa MI, Zhang JG, Culibrk B, et al. Novel system for storage of buffy-coat-derived platelet concentrates in a glucose-based platelet additive solution: parameters and metabolism during storage and comparison to plasma. Vox Sang 2009;97:102-9.
26. Blumberg N, Gettings KF, Turner C, et al. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. Transfusion 2006;46:1813-21.
27. Hamzeh-Cognasse H, Damien P, Nguyen KA, et al. Immune-reactive soluble OX40 ligand, soluble CD40 ligand, and interleukin-27 are simultaneously oversecreted in platelet components associated with acute transfusion reactions. Transfusion 2014;54:613-25.
28. Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006;108:2455-62.
29. Phipps RP, Kaufman J, Blumberg N. Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion. Lancet 2001;357:2023-4.
30. Van der Meer PF, De Korte, D. Platelet additive solutions. In: Joseph D, Sweeney ML, editors. Platelet transfusion therapy. Bethesda: AABB Press; 2013. p. 75-118.
31. Harvey AR, Basavaraju SV, Chung KW, et al. Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012. Transfusion 2015;55:709-18.
32. Rogers MA, Rohde JM, Blumberg N. Haemovigilance of reactions associated with red blood cell transfusion: comparison across 17 countries. Vox Sang 2016;110:266-77.